Background. Chronic kidney disease (CKD) develops frequently after liver transplantation (LTx), and it is important to identify and correct risk factors that negatively affect kidney function. Risk factors have not been well evaluated in Asian countries where hepatitis B virus (HBV) infection is a dominant cause. Methods. Four hundred thirty-one Korean recipients who underwent LTx between 1997 and 2008 were analysed. CKD was defined as a sustained decrease in estimated glomerular filtration rate (eGFR) of <60 (mL/min/1.73 m 2 ) for at least three consecutive months using an abbreviated Modification in Renal Disease (MDRD) formula. Results. Eighty percent of the patients had HBV-related underlying diseases. The recipients whose pretransplant eGFR had been low (<30 mL/min/1.73 m 2 ) improved their renal function after LTx, but significant functional decline occurred in recipients whose pretransplant eGFR was high (≥60 mL/min/1.73 m 2 ). A multivariate Cox regression analysis revealed that the overall risk of CKD development (eGFR < 60 mL/min/1.73 m 2 ) was associated with old age of recipients, cyclosporine, posttransplant acute renal failure (ARF), cause [calcineurin inhibitor (CNI) nephrotoxicity] and severity of posttransplant ARF, low pretransplant eGFR, pretransplant hepatorenal syndrome, pretransplant proteinuria, high Child-Pugh score and high Model for End-Stage Renal Disease (MELD) score. Especially in recipients whose pre-operative eGFR was high (≥60 mL/min/ 1.73 m 2 ), rapid progression of kidney disease was associated with high tacrolimus level, non-HBV disease, posttransplant ARF, cause (CNI nephrotoxicity) and severity of posttransplant ARF and Child-Pugh score. CNI toxicity and focal segmental sclerosis, but not immune-complex disease, were revealed as significant contributors to CKD after LTx in HBV recipients.
Introduction
Chronic kidney disease (CKD) is a common problem in long-term survivors after liver transplantation (LTx). The prevalence of CKD ranges from approximately 20% to 70%, and the occurrence of CKD significantly increases the mortality in liver recipients [1, 2] . Recently, several studies were conducted to clarify the risk factors for CKD progression, such as the use of calcineurin inhibitors (CNIs) and preoperative kidney function [1, 3, 4] . Asian ethnicity, in comparison to other ethnic groups, has been suggested as a good prognostic factor for the development of CKD after LTx [1] , but a reason for this has never been documented.
In Western countries, liver disease caused by hepatitis C virus (HCV) linked with glomerulonephritis is the leading indication for liver transplantation, accounting for 30% to 50% of cases [1, 5, 6] . However, an Asian institute, specifically the Korean Society, developed a distinctive strategy for the institution of liver transplantation in treating liver failure [7] . Hepatitis B virus (HBV) infection is more prevalent in Korea as well as in other Asian countries where the vertical transmission of HBV is a major route of infection. It implies the long duration of infection, which has a potential to cause serious liver diseases such as liver cirrhosis and hepatocellular carcinoma. These distinctions between Asians and Caucasians may explain not only the difference in frequency but also in the main cause of kidney dysfunction after LTx. We previously reported the features of CKD after LTx in Korea [8] , but this report had limitations due to the insufficient number of recipients examined and the short duration of follow-up.
The purpose of this study was to delineate the risk factors associated with progressive kidney dysfunction after LTx in recipients with HBV infection, the main indication for liver transplantation in Korea.
Additionally, we reviewed kidney biopsy cases performed after liver transplantation in recipients with HBV infection to explain the above-mentioned ethnic differences because biopsy serves as a unique way to understand the exact cause of kidney dysfunction [5, 9, 10] .
Materials and methods

Study population
We studied the clinical records of 604 consecutive Korean LTx patients who underwent LTx between 1997 and 2008 at our institute. Data from 173 recipients who received multi-organ transplantation, had a short follow-up duration (<6 months), died within 6 months after transplantation, or were <18 years old were excluded. Medical records were reviewed retrospectively. Clinical parameters that could have influenced development of chronic kidney disease were collected, i.e. age at transplantation, gender, era, history of hypertension and diabetes mellitus, underlying disease, history of hepatocellular carcinoma, body mass index (BMI), pretransplant proteinuria, Child-Pugh score, Model for End-Stage Disease (MELD) score, hepatorenal syndrome, posttransplant acute renal failure (ARF), aetiologies of ARF, history of cardiovascular disease, donor type and immunosuppressant. Also, information on the agents used to treat hepatitis B virus infection such as adefovir or tenofovir, which are known to be nephrotoxic in some patients was collected. Hepatitis B viraemic status was measured with serum HBV DNA polymerase chain reaction (PCR) at and after transplantation.
Measurement of kidney function and definition of CKD and ARF
Serum creatinine was measured with a commercially available assay based on the modified Jaffé method reported by Larsen [11] . CKD was defined as a sustained decrease in estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m 2 for at least three consecutive months using an abbreviated Modification in Renal Disease (MDRD) formula [=186 × (serum creatinine mg/dL) −1.154 × (age) −0.203 × (0.742 if female)]. Severe CKD was defined as an eGFR < 30 mL/min/1.73 m 2 for at least three consecutive months. Posttransplant ARF was defined using the RIFLE criteria [12] . The aetiological categories of ARF, i.e. prerenal ARF, ischaemic acute tubular necrosis (ATN) and CNI nephrotoxicity were defined as described previously [13] . Hepatorenal syndrome was considered when all the major criteria of the International Ascites Club were fulfilled [14] .
Definitions of other clinical parameters
Hypertension was defined as a systolic blood pressure over 140 mmHg, diastolic pressure over 90 mmHg or the use of anti-hypertensive medication. Presence of diabetes mellitus was diagnosed if patients had symptoms and had a random blood glucose concentration ≥200 mg/dL or if fasting plasma glucose was ≥126 mg/dL on at least two separate measurements or if patients used antidiabetic medication. MELD scores were calculated for each patient using the following equation: (0.957 × log (e) (serum creatinine mg/dL) 0.378 × log (e) (serum bilirubin mg/dL) 1.120 × log (e) (PT International normalized ratio) 0.643) × 10. Proteinuria was defined as 1 or more on the dipstick urinalysis.
Immunosuppressive treatment protocols
A standardized immunosuppression protocol involving a combination of CNIs and steroids was initiated within 24 h of surgery. Choice of calcineurin inhibitor between cyclosporine and tacrolimus was determined by a transplantation team. In recipients with preoperative renal insufficiency, hepatitis C virus infection, or presence of diabetes, cyclosporine-based immunosuppression was preferable to tacrolimus-based immunosuppression. In cases receiving cyclosporine-based treatment, the trough level was maintained between 200 and 300 ng/mL for the first 3 months and was reduced to 100~200 ng/mL thereafter. In the tacrolimus-based protocol, the trough level was 8~13 ng/mL for the first 3 months and decreased to 5~100 ng/mL thereafter. When the recipient had poor renal function at the time of operation, the trough level of CNIs was maintained at a relatively low level, especially in recipients with eGFR <30 mL/min/1.73 m 2 .
Prednisolone was started at 20 mg/day and gradually tapered. Routine liver biopsy was performed on posttransplant day 10.
Purine synthesis inhibitors such as mycophenolate mofetil were used as an initial immunosuppressive treatment based on a clinical decision that considered the pretransplant kidney function, results of the protocol biopsy and risk factors of rejection [e.g. human leukocyte antigen (HLA) mismatch]. It was more frequently used from the initiation of immunosuppression when the renal function was significantly compromised.
Kidney biopsy and histopathologic lesion
Kidney biopsy was performed after the need for percutaneous kidney biopsy was evaluated by nephrologists in the case of significant proteinuria (>1.0 g/day), persistent microscopic haematuria or a progressive deterioration of renal function. Biopsy tissue was examined by light-, electron-, and immunofluorescent (IF) microscopy.
All specimens were reviewed by an experienced kidney pathologist at the same time. Diabetic glomerulosclerosis was determined by light microscopy as well as IF using specific linear staining for IgG and albumin along the glomerular capillary walls and tubular basement membranes. CNI toxicity was diagnosed when biopsy specimens revealed the pattern of interstitial fibrosis with a 'striped' appearance, nodular arteriolar hyalinosis and, later, tubular atrophy with glomerulosclerosis and arteriosclerosis. The number of focally or completely sclerosed glomeruli was scored as a percentage of the total number of glomeruli seen on each biopsy. Tubulointerstitial fibrosis was graded as +1 (0∽24%), +2 (25∽49%), +3 (50∽74%), and +4 (75∽100%). Vascular damage was also graded semiquantitatively as 0 to +3.
Statistical methods
The statistical analysis was performed using SPSS 12.0 K (SPSS Inc, Chicago, IL, USA). Data were expressed as means ± SD. Continuous and categorical data were compared using the independent t-test and the chi-squared test, respectively.
Cumulative incidence of CKD was calculated using the Kaplan-Meier method. The Cox regression model was used to calculate unadjusted and adjusted hazard ratio (HR) and 95% confidence interval (CI) for factors that affect the development of CKD. The interactions among variables for adjustments were determined using the general linear model. To compare the effects of variables on graft survival, we used the backward stepwise selection in the Cox regression model. Logistic regression analysis was used to discover risk factors for rapid progression of kidney dysfunction. P-values <0.05 were considered significant.
Results
Baseline characteristics
A total of 431 adult recipients [male:female 312:119, mean age (±SD) 48 ± 9.2 years old], were included, and the follow-up duration was 46 ± 31.4 months. Eighty percent of LTx cases were due to HBV-related diseases (liver cirrhosis and hepatocellular carcinoma) ( Table 1 ). The proportion of viraemic patients at transplantation was 82.3% in the HBV recipients. Almost all of them were treated with antiviral agents such as lamivudine and adefovir. Hepatocellular carcinoma was found in 40% of the recipients. The deceased donor transplantation rate was 23%. During the follow-up period, biopsy-proven acute re- Target range of cyclosporine: 200∽300 ng/mL at 1 and 3 months, 100∽200 ng/mL at 6 and 12 months; target range of tacrolimus: 8∽13 ng/mL at 1 and 3 months, 5∽10 ng/mL at 6 and 12 months. f Fisher's exact test. 2774 J.P. Lee et al. jections were found in 9.2% of patients. The proportion of patients with hepatorenal syndrome was 12.1%. The mean Child-Pugh and MELD scores (±SD) were 10.6 ± 2.6 and 21.0 ± 10.0, respectively. Posttransplantation ARF was documented in 27.4% of the recipients. The most common cause was ischaemic ATN (44.1%), followed by prerenal ARF (27.1%) and CNI nephrotoxicity (16.9%). Fourteen recipients (3.2%) had ARF of sufficient severity as to require renal replacement therapy after liver transplant surgery. Twenty-three (5.3%) deaths were observed during the follow-up period. The causes of death were as follows: 8 from infection, 10 from recurrence of hepatocellular carcinoma, 4 from hepatic failure due to rejection and 1 from cardiovascular disease.
Kidney function after liver transplantation and incidence of chronic kidney disease
The mean eGFR (mL/min/1.73 m 2 , ± SD) was 82 ± 30.0 mL/min/1.73 m 2 before transplantation, 67 ± 18.6 mL/min/1.73 m 2 at 6 months, 68 ± 17.8 mL/min/ 1.73 m 2 at 1 year, 69 ± 16.3 mL/min/1.73 m 2 at 3 years and 68 ± 16.8 mL/min/1.73 m 2 at 5 years ( Figure 1A ). Kidney function gradually deteriorated until 6 months after transplantation but was maintained thereafter. The cumulative incidence of CKD (eGFR < 60 mL/min/1.73 m 2 ) was 17.6% at 1 year, 23.7% at 3 years and 27.5% at 5 years ( Figure 1B ). An eGFR < 30 mL/min/1.73 m 2 occurred in only five patients during follow-up ( Figure 1C) . One patient was on long-term renal replacement therapy.
Risk factors for CKD
A multivariate Cox regression analysis revealed that the overall risk of CKD (eGFR <60) was associated with old age of recipients, cyclosporine, posttransplant ARF, the cause and severity of posttransplant ARF, low pretransplant eGFR, pretransplant hepatorenal syndrome, pretransplant proteinuria, high Child-Pugh score and high MELD score (Table 2) . However, diabetes, hypertension, HCV infection, type of donor, acute rejection and pretransplant existence of hepatocellular carcinoma were not associated with CKD development. The risk for CKD was increased by 1.07 times as the age of recipient increased by 1 year. Cyclosporine-based immunosuppression increased the risk by 1.89 times in comparison to tacrolimus-based treatment. The posttransplant ARF increased the risk by a factor of 1.54. Additionally, the cause and severity of posttransplant ARF were related to the risk of CKD (Table 2, Figure 2 ). The Risk group did not increase the risk of CKD, but the Injury group increased the risk by 3.04 times in comparison to the non-ARF group. Prerenal ARF or ischaemic ATN could not increase the risk, but CNI nephrotoxicity significantly increased the risk by a factor of 4.24.
Impact of preoperative eGFR and progression of chronic kidney disease
We observed a change in posttransplant kidney function depending on pretransplant eGFR. Recipients with low eGFR (pretransplant eGFR <60 mL/min/1.73 m 2 ) were older and had higher Child-Pugh scores, and the propor- tion of males was lower at the time of transplantation (Supplement Table 1 ). In addition, CNIs were maintained at a lower trough level, and the use of mycophenolate mofetil was relatively higher in these patients compared to patients with higher eGFR.
Kidney function was significantly improved in the low eGFR group (pretransplant eGFR ≤ 29 mL/min/1.73 m 2 ) during the f irst 6 months (from 18 ± 7.1 to 48 ± 16.0 mL/min/1.73 m 2 ), which was maintained afterwards.
In the low-intermediate eGFR group (pretransplant eGFR 30-59 mL/min/1.73 m 2 ), there was no significant change in kidney function. Recipients with pretransplant eGFR ≥ 60 mL/min/1.73 m 2 showed a significant reduction in kidney function during the first 6 months (Figure 3) . Therefore, we assumed that it was critical to identify factors related to the decline of kidney function during the first 6 months after transplantation, especially in the recipients with good preoperative kidney function. 
Subgroup analysis in recipients with good preoperative kidney function
First, we performed a subgroup analysis of factors associated with development of posttransplant CKD in 'recipients with pretransplant eGFR ≥60 mL/min/1.73 m 2 '. A multivariate Cox regression analysis revealed that pretransplant low haemoglobin level and non-HBV disease as well as the previously described risk factors including old age of recipients, cyclosporine, posttransplant ARF and causes (ischaemic ATN and CNI nephrotoxicity) and severity of posttransplant ARF were revealed as risk factors (Table 3) .
We compared serial eGFR changes between recipients treated with either tacrolimus or cyclosporine in recipients with a pretransplant of eGFR ≥ 60 mL/min/1.73 m 2 . Although both groups had similar pretransplant eGFR and the trough level of cyclosporine was not higher than that expected, the posttransplant eGFR of recipients treated with cyclosporine was signif icantly decreased after 6 months ( Figure 4) .
Next, according to the rate of deterioration in renal function (ΔGFR) during the first 6 months after transplantation, we divided the recipients using tacrolimus into rapid progression group (ΔGFR ≥40, n = 55), slow progression group (ΔGFR 20-39, n = 78) and stable group (ΔGFR ≤ 19, n = 158). The trough level of the tacrolimus was significantly higher in the rapid progressive group compared to other two groups ( Figure 5 ). When the rapid progression group and the stable group were compared by multivariate logistic regression, non-HBV disease, posttransplant ARF, cause (CNI nephrotoxicity) and severity of posttransplant ARF and Child-Pugh score were acknowledged as significant risk factors for rapid progression in addition to the tacrolimus trough level (Table 4 ). This subgroup analysis was not done on those treated with cyclosporine due to the low number of each group [rapid progression group (n = 11), slow progressive group (n = 22) and stable group (n = 17)].
Kidney histopathology after LTx in patients with hepatitis B virus-associated liver disease
Kidney biopsy was performed in nine recipients with HBV-related liver disease (Table 5) . Eight recipients had progressive azotaemia [median serum creatinine at kidney biopsy 2.3 (1.9~3.0) mg/dL], and one (case 8) had newly developed proteinuria (random urine protein/creatinine 2.67 mg/mg, serum creatinine 1.2 mg/dL).
The median time from transplantation to kidney biopsy was 11.3 (4.7~77.9) months. Chronic CNI toxicity was detected in five cases (55.6%), and none of these had overt proteinuria. In the remaining four cases with proteinuria over 1 mg/mg (spot urine protein/creatinine), two had Fig. 4 . Comparison of kidney function between recipients treated with tacrolimus and with cyclosporine after liver transplantation (mean ± SD, independent t-test, *P < 0.05; **P < 0.01); pre-Tx, pretransplant.
IgA nephropathy (considered as associated with liver cirrhosis), one had prominent diabetic glomerular change, and one had severe sclerotic change and tubulointerstitial fibrosis similar to end-stage renal disease. Three cases had focal segmental sclerosis. However, HBV-related immunecomplex glomerulonephritis (GN) [e.g. membranous nephropathy or membranoproliferative GN (MPGN)] was not found (Table 5 ). Based on the results of the kidney biopsy, either a change in immunosuppressant or the addition of angiotensin receptor blockers was applied to the recipients. Only one recipient progressed to end-stage renal disease after the kidney biopsy, and the remainder demonstrated improvement in kidney function or complete remission of proteinuria.
Discussion
This work evaluated the incidence and risk factors of chronic kidney disease following liver transplantation in a cohort of transplant patients of a single Asian centre where the prevalence of HBV infection is high.
Although there have been several studies examining kidney dysfunction after liver transplantation, deceased donor transplantation and liver failure caused by non-HBV disease were the main features of the study populations [4, [15] [16] [17] [18] . In previous work by Ojo et al., more than 36 000 liver recipients were analysed, but only 5.6% of them were HBV(+) [1] . In this setting, HBV infection was not a significant risk factor compared to other causes comprising the rest of the recipients (94.4%). HBV infection, however, was the major cause of liver disease (80%) in our study population. In our cohort, we may compare the significance of specific viral infection such as HBV or HCV for the development of CKD. Therefore, this study provides important information that should be considered in the treatment of patients with different ethnic and epidemiologic backgrounds.
We used creatinine-based GFR calculated with the abbreviated MDRD formula to assess renal function. Recently, several studies have tried to modify the formula with the Asian's own coefficients [19] [20] [21] [22] . We also obtained Korean racial coefficients [four-and six-variable isotope dilution mass spectrometry (IDMS) MDRD] from the study 'Measurement of glomerular filtration rate and calculation of GFR estimates for Korea', granted by the Korean Society of Nephrology. Racial coefficients of four-and six-variable IDMS MDRD study equations using recalibrated serum creatinine were 0.99096 and 0.9554, respectively (manuscript in preparation). Therefore, the usage of creatinine for the estimation of GFR in Asians, especially in Koreans, is appropriate and validated.
The overall incidence of CKD in the present study was much lower than that in other studies [1, 4, 15, 16] , even though the definitions for CKD varied. It is consistent with the finding that Asian ethnicity may be a good prognostic factor for the development of CKD [1] . The decline of kidney function during the first 6 months was faster than that of later periods, and this finding is also similar to previous studies [3, 16, 17, 23] .
Through observing kidney function at sequential time points in comparison to the pretransplant eGFR, we noted that kidney function declined to a greater degree in the high eGFR subgroup (eGFR ≥ 90 mL/min/1.73 m 2 ). On the other hand, recipients with low kidney function (eGFR ≤ 29 mL/min/1.73 m 2 ) demonstrated a significant improvement in kidney function. Consequently, the mean eGFR in each subgroup progressed toward a common mean. A unique finding of our work is that liver transplantation showed a differential impact on kidney function depending on the pretransplant eGFR.
This study identified old age, low pretransplant eGFR, use of cyclosporine, low pretransplant haemoglobin, posttransplant ARF, cause (CNI nephrotoxicity) and severity of posttransplant ARF, pretransplant hepatorenal syndrome, pretransplant proteinuria, high Child-Pugh score, high MELD score, non-HBV infection and high trough level of CNIs as independent risk factors from multivariate risk analysis and the subgroup analysis in the pretransplant high eGFR recipients (eGFR ≥ 60 mL/min/1.73 m 2 ). . Trough tacrolimus level depending on the rate of kidney dysfunction progression during first 6 months posttransplant. ΔGFR, rate of kidney dysfunction progression during first 6 months posttransplant; stable, ΔGFR ≤ 19 (n = 150); slow progressor, ΔGFR 20-39 (n = 76); rapid progressor, ΔGFR ≥ 40 (n = 54) (mean ± SD, ANOVA test, *P < 0.05; **P < 0.01; ***P < 0.001); prog, progressor.
Our results revealing old age, posttransplant ARF, low pretransplant eGFR, pretransplant hepatorenal syndrome, pretransplant proteinuria, high CNI trough levels and use of cyclosporine as risk factors of CKD after liver transplantation corresponded with the previous studies [1, 3, 4] . As with Ojo et al. [1] , this study presents cyclosporine as a significant risk factor for CKD in the multivariate Cox regression analysis. Although tacrolimus may be less nephrotoxic by diminished vasoconstriction and by reduced expression of cytokines such as TGF-β [24] , the beneficial effect of tacrolimus is still controversial [25] [26] [27] .
Preoperative MELD score or Child-Pugh score have been known to be related with recovery from hepatorenal syndrome, posttransplant haemodialysis and early acute renal failure [13, 18, 28] . But the finding that the severity of liver disease is related with development of CKD after liv- 
